Hi, everyone. Good morning. My name is Priyanka Grover, and welcome to the 41st annual JP Morgan Healthcare Conference. I'm joined by Senior Analyst Anupam Rama and Fellow Associate Malcolm Kuno. Today we'll be hearing from Elevation Oncology, followed by a Q&A session. I'd like to present Interim CEO and CFO, Joseph Ferra, who will present on behalf of Elevation Oncology. Thank you. Thank you, Priyanka. Thank you to the JP Morgan team. Thank you all for joining me today. I'm Joe Ferra, Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology. I look forward to telling you more about our company today and telling you more about our focus on making a difference for patients suffering from cancer. Please note that during this presentation, I'll be making some forward-looking statements. For complete review of our risk factors, I invite you to visit our website and also our SEC filings. Today, I'm gonna spend most of our time together talking about our lead program, EO-3021, a potential best-in-class Claudin 18.2 antibody-drug conjugate. Our partner, CSPC, is currently conducting a phase I clinical trial in China, and we've said that we expect to enter into a phase I trial in the U.S. in the 2nd half of this year. We are also continuing to invest in our pipeline and focusing on novel selective cancer therapies, including those through our partnership with Caris Life Sciences. We have a strong management team with deep expertise in bringing oncology agents to patients and making a difference in their lives. We're a strong company with a cash position and a runway into the fourth quarter of 2024. We are building a novel selective cancer therapy pipeline led by EO-3021. As I said, we plan to initiate a phase I clinical trial in the U.S. in the second half of this year. Our additional pipeline programs are focused on novel therapeutic drug candidates and targets, including those through our partnership with Caris Life Sciences. Last week, we announced a pipeline prioritization, a reorganization focusing around our lead program 3021. As part of that announcement, we announced that we are pausing further investment of seribantumab, an anti-HER3 monoclonal antibody, on our own and will only seek further investment in the program along with a partner. Last year at ASCO, we released positive proof-of-concept clinical data for this program, showing that it makes a difference for patients with NRG1 fusion-driven cancers. We've also said that later this year, in the first half, we will present the next update of data from that study, the CRESTONE study. We believe seribantumab is a differentiated asset that can make a difference for these patients. We believe that further investment in the program is best suited only along with a partner. EO-3021 is a potential best-in-class antibody-drug conjugate targeting Claudin 18.2. Claudin 18.2 is a validated clinical target with a significant potential market opportunity across many cancers, including many GI cancers. Our partner, CSPC, is currently conducting a phase I clinical trial in China. The IND in the U.S. is already cleared, and we plan to initiate our study starting in the U.S. in the second half of this year. Important to note that there are no currently approved therapies for patients with cancers that highly express Claudin 18.2. There's a meaningful opportunity here to make a difference for these patients and meet this significant unmet need. Claudin 18.2 is a highly selective cell surface target that is overexpressed in a range of solid tumors. Expression is usually restricted to the gastric mucosa, overall making it an ideal target for ADC, antibody-drug conjugate approach. The patient population currently has very limited treatment options, as the expression does not overlap with other agents that are currently approved, such as HER2 and PD-L1. With no currently approved therapies, making a drug for Claudin 18.2 expression also makes it an ideal therapeutic target. EO-3021 is a potential best-in-class ADC. Just like many other ADCs, it binds to tumor cells overexpressing Claudin 18.2 and delivers the payload. In the case of 3021, MMAE payload, inducing apoptosis and resulting in cell death. There's a significant opportunity to help these patients. Claudin 18.2 expression is represented across several cancers and affects millions of patients worldwide. Since it's most prevalent in gastric, esophageal, and pancreatic, there's a meaningful opportunity worldwide, and we, as a company, have worldwide rights to the drug outside of Greater China. Claudin 18.2 expression is also high in ovarian and lung cancers. There have been many agents recently that have shown clinical data that support that the clinical effect of targeting Claudin 18.2 is meaningful for these patients and makes a difference. They've shown improvement across a range of tumors. Has shown that with doing so, you can make a difference in the outcomes of these patients. These agents, in this case, a naked monoclonal antibody and also CAR T therapy, generally are focused on those tumors that are high expressers and moderate expressers of Claudin 18.2 as measured by IHC. However, we know there are many more patients out there that also have low expressers of Claudin 18.2, and if these agents continue further, those patients may still be underserved. Part of the reason why we are very excited about EO-3021 and an ADC approach here is the opportunity to not only treat the high and the moderate expressers of Claudin 18.2, but also the low expressers. The CAR T approaches, the monoclonal antibody approaches are making a difference in this unmet need, and we hope for the sake of patients that they are able to be delivered to them in improved therapies. We think they still leave something on the table. With an ADC approach, particularly with an agent like EO-3021, we think we can be more completely treat patients across the range of Claudin 18.2 expression. We see the landscape of Claudin 18.2 expression evolving as we have with other types of treatment examples, particularly with HER2. Where initially you see chemotherapy have an effect and including agents in combination with chemotherapy, then you move towards naked monoclonal antibodies. You see TKI inhibitors, and eventually an ADC approach wins the day, just as we're seeing with HER2, because delivering a payload selectively to the target can ultimately have a better effect for the patient. We've said that we expect to enter clinical trials for EO-3021 in the second half of this year. A reminder that there's an ongoing phase I study in China through our partner, CSPC, who's currently running a dose escalation study. The IND is cleared in the U.S., and we are planning to show preclinical proof of concept data in the first half of this year as an initial showing of what we think 3021 has the potential to do for patients. In addition to 3021, we are also very focused on investing further in our pipeline and finding additional selective cancer therapies that can make a difference in the future. This includes through our partnership with Caris Life Sciences. Caris Life Sciences is one of the leading genomic testing providers in the U.S. and has a broad array of whole transcriptome, whole genome data that we are working with them to understand the next generation of genomically defined drivers of cancer. With this data, we hope to find additional targets that are either known or not known that can make a difference for patients towards the future. Based on the targets that we select, we may choose to either enter into a drug development effort on our own or explore business development opportunities that are already out there, as we have done in other cases. It's gonna be an exciting year for us as a company led by EO-3021. In the first half of this year, we will have present preclinical proof of concept data at a major medical meeting, and as I've said, we plan to start our U.S. phase trial in the second half of 2023. We're also gonna update the seribantumab data as we move towards a partnership approach for that drug, showing the next layer of CRESTONE data in the first half of 2023. We have a strong cash position to execute on all this, with $90.3 million of cash and cash equivalents as of the end of 2022, and a cash runway into the fourth quarter of 2024. We look forward to telling you a lot more about what we're doing about Elevation Oncology as the year progresses. Thank you for your time, and again, thank you to the JP Morgan team. All right, we are going to start the Q&A session. If there are any questions, please feel free to email us or use the question portal or raise your hands and a mic will be brought to you. We are now being joined with the rest of the Elevation Oncology team. I will start off with the first question. Sure. With the recent changes that have occurred to the company, can you provide a timeline to full-time CEO? Sure. As we said in our release on Friday, I've been named interim chief executive officer. The board and the company is focused on the leadership team that we have in place now, and we look forward to executing on everything going forward. How much did the regulatory process for competitors play into the decision to deprioritize? Valerie, would you like to take that question? Yeah. I mean, as we saw at ASCO, you know, seribantumab has this great potential to help patients with solid tumors that harbor NRG1 fusion. I think, you know, we all understand the changing, evolving landscape with FDA and Accelerated Approval as well as tumor-agnostic. You know, it did have in terms of our discussion. However, we think that with the right partner, we can continue to bring seribantumab and to be able to help patients. It's an evolving landscape, and certainly in terms of the overall focus on what we believe is a greater potential to help even more patients with EO-3021. We have one question here. 30/21. Can you give us a little more color on maybe some of the financial aspects of that collaboration and how it might affect your... Sorry. I know. The question was regarding the financial details of the EO-3021 collaboration deal. Sure. The, the runway that we stated into Q4 2024 obviously includes everything involved with starting up the EO-3021 trial in the U.S. and executing it over that time period. Our deal with CSPC, our agreement with CSPC is a very attractive deal with economics that are very back-end loaded. There's additional milestones due of $148 million between clinical and regulatory milestones, as well as about $1 billion in sales milestones going forward. Royalties in addition to that. All of those are later later down the line as we continue to develop EO-3021 in our territories outside Greater China. I'll ask the next question. What kind of partnerships are you seeking for the seribantumab program? You know, the seribantumab program is very much a precision oncology type program. Most of the meaningful partners there will be those that understand precision oncology, which in and of itself is a very unique approach in oncology. We look forward to talking more about potential partnerships there as time goes on. I'll ask another question. How are you thinking about building around the Claudin program? Claudin 18.2 expression, we believe, is one of the next generations of really meaningful targets in oncology. As I said in the presentation, there's a range of tumors where expression can be used to help those patients. We see this as initially a monotherapy approach as an ADC, but with success and with time, we can think of additional approaches for EO-3021 that can make a lot of sense, making a very multilayered type of development program over time. I guess I have one final question. How are you thinking about the win scenario for the phase I Claudin program? Valerie, would you like to take that question? Yeah. I mean, you know, of course we know that it's a competitive landscape, which makes the target that much more interesting to pursue and a validated clinical target, especially with the monoclonal zolbetuximab program. I think a win just certainly would be in terms of getting proof of concept data as quick as possible in the U.S., we have the luxury of our partner conducting that study in China and learning from that experience. For us, it'll be really critical in terms of dosing that first patient in that second half of 2023, if not sooner. Understood. If there are no more questions, thank you so much. Thank you to the JP Morgan team for hosting us, and thank you all for joining us today.